Dambkowski Carl 4

What Happened Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), executed a combination of option exercises and an open-market sale on July 1, 2026. He exercised options to acquire 4,125 shares at $22.86 per share (total cash paid ~$94,298). He also reported a derivative disposition of 4,125 shares at $0 (reported as part of the same exercise events) and sold 5,500 shares in an open-market transaction for $132.74 per share (total proceeds $730,070). The sale was executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: July 1, 2026 (reported July 2, 2026)
• Option exercise: 4,125 shares acquired at $22.86; cash paid $94,298
• Derivative disposition: 4,125 shares reported at $0 (disposition related to the exercise)
• Open-market sale: 5,500 shares sold at $132.74; proceeds $730,070
• Footnotes: F1 — sale executed pursuant to a Rule 10b5-1 plan adopted Sept 22, 2025; F2 — the option relates to a grant covering 175,345 shares that vest in 48 monthly installments through Dec 18, 2027 (subject to continued service)
• Shares owned after transaction: Not disclosed in the provided filing
• Filing timeliness: Reported the next day (not indicated as late)

Context This filing shows both an option exercise (insider acquired shares by exercising options) and an open-market sale executed under a 10b5-1 plan (often used to pre-schedule sales). Purchases (option exercises) can be viewed as acquisition activity, while sales under a 10b5-1 plan are often routine and follow a pre-set schedule; the filing itself does not state the insider’s motivation.